Compare Citius Pharmaceuticals Inc (CTXR) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs LTC Properties Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.68 (market cap $20.01M), while LTC Properties Inc trades at $38.74 (market cap $2.05B). The key difference: LTC Properties Inc is far larger — about 102.4× Citius Pharmaceuticals Inc's market cap, and LTC Properties Inc pays a 5.98% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LTC | |
|---|---|---|
Market Cap | $20.01M | $2.05B |
Sector | Health | Real Estate |
52-Week High | $1.82 | $42.81 |
52-Week Low | $0.48 | $33.98 |
Enterprise Value | $16.23M | $2.79B |
Dividend Yield | — | 5.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
LTC Properties (LTC) trades at $38.32, down 2.79% over 24 hours, with a bullish technical signal driven by moving averages. The REIT shows strong profitability with a 61.72% gross margin and 38.93% net margin, though recent earnings missed estimates in two of the last three quarters. Recent news highlights aggressive expansion in seniors housing acquisitions, including a $95 million SHOP purchase announced August 5, 2026.
Outlook is mixed: demographic trends support long-term demand, but execution risks from rapid growth and debt-funded investments pose challenges. Analysts are cautious with 59% hold ratings, reflecting concerns over earnings consistency amid high capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
